Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
Authors:
- 15 January 2009
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 24 (1) , 129-133
Abstract
There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder SocietyKeywords
This publication has 18 references indexed in Scilit:
- Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's diseaseThe Lancet Neurology, 2007
- Dopamine Agonists and the Risk of Cardiac-Valve RegurgitationNew England Journal of Medicine, 2007
- Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader‐blinded monocenter echocardiography studyMovement Disorders, 2006
- Cabergoline-Related Severe Restrictive Mitral RegurgitationNew England Journal of Medicine, 2005
- Pleural effusion and thickening due to cabergoline use in a patient with Parkinson's diseaseEuropean Journal of Internal Medicine, 2005
- Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non‐ergot agonists may also not be sparedMovement Disorders, 2004
- Diagnosis and management of pergolide‐induced fibrosisMovement Disorders, 2004
- Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolideNeurology, 2003
- Pleural fibrosis associated with dihydroergocryptine treatmentActa Neurologica Scandinavica, 2000
- Pleuropulmonary changes induced by ergoline drugsEuropean Respiratory Journal, 1996